Belgium· BE-AMP-SAM583386-00
Byfavo 20 mg
A remimazolam product containing remimazolam besilate, registered in Belgium by Paion Pharma. The same ATC class is registered in 14 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Remimazolam is registered in 14 of 19 countries.
Countries holding a registration under ATC N05CD14 (remimazolam), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 9 of them publish a price we can compare per daily dose
Remimazolam · ATC N05CD14
14 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- United Kingdom
- United Statesprice
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Remimazolam Besilate
- Manufacturer
- Paion Pharma
- Country
- Belgium (BE)
- ATC code
- N05CD14
- ATC class
- Remimazolam
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 1
- be_apb4727756
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
71 interactions on record for remimazolam.
Graded by severity as the source publishes them — 4 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Remimazolam · interactions on record
71 records
- 4 severe
- 64 moderate
- 3 minor
Most severe, free to view
- MorphineN02AA01severe
- MorphinN07BC09severe
- HydrocodoneR05DA03severe
- CodeineR05DA04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Remimazolam in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NorwayByfavoPAION Pharma GmbH
- CzechiaBYFAVOPAION Pharma GmbH, Aachen
- SpainBYFAVO 20 MG POLVO PARA SOLUCION INYECTABLEPaion Pharma Gmbh
- United KingdomByfavo 20mg powder for solution for injection vialsPAION Pharma GmbH
- PolandByfavoPAION Deutschland GmbH
- SwedenByfavo 20 mg Pulver till injektionsvätska, lösningPAION Pharma GmbH
- FinlandByfavoPAION Pharma GmbH
- IrelandByfavo 20 mg powder for solution for injectionPaion Pharma GmbH
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Byfavo
- Liechtenstein · Byfavo
- Norway · Byfavo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/194de313-7389-42f8-9d5d-3c50d52bb6e8 GET /v1/drugs/194de313-7389-42f8-9d5d-3c50d52bb6e8?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Powder for solution for injection",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Byfavo 20 mg",
"name_fr": "Byfavo 20 mg",
"name_nl": "Byfavo 20 mg",
"amp_code": "SAM583386-00",
"strengths": [
"20.0000",
"20.0000",
"20.0000"
],
"pack_count": 1,
"substances": [
"Remimazolam Besilate",
"Remimazolam",
"Lactose Monohydrate",
"Sodium Hydroxide"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Remimazolam",
"authorisation_numbers": [
"EU/1/20/1505/001"
]
}See everything about remimazolam.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.